QuidelOrtho Corporation (QDEL)

NASDAQ: QDEL · Real-Time Price · USD

22.48

-1.13 (-4.79%)

At close: Feb 20, 2026, 4:00 PM EST

22.85

+0.37 (1.65%)

After-hours: Feb 20, 2026, 7:38 PM EST

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014
Period Ending	Dec '25 Dec 28, 2025	Dec '24 Dec 29, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 2, 2022	Jan '21 Jan 3, 2021	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014
North America Revenue	1.49B	1.62B
North America Revenue Growth	-8.08%	-13.71%
EMEA Revenue	360.70M	335.80M
EMEA Revenue Growth	7.41%	2.60%
China Revenue	334.70M	325.00M
China Revenue Growth	2.99%	4.81%
JPAC Revenue	293.00M	279.40M
JPAC Revenue Growth	4.87%	-
Latin America Revenue	252.90M	222.90M
Latin America Revenue Growth	13.46%	-
Other Geographies Revenue	545.90M	502.30M
Other Geographies Revenue Growth	8.68%	3.93%
Revenue (Total)	2.73B	2.78B
Revenue (Total) Growth	-1.89%	-7.17%

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014
Period Ending	Dec '25 Dec 28, 2025	Dec '24 Dec 29, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 2, 2022	Jan '21 Jan 3, 2021	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014
Labs Revenue	1.51B	1.43B
Labs Revenue Growth	5.50%	0.13%
Immunohematology Revenue	543.80M	522.00M
Immunohematology Revenue Growth	4.18%	1.87%
Donor Screening Revenue	52.60M	115.10M
Donor Screening Revenue Growth	-54.30%	-15.43%
Transfusion Medicine Revenue	596.40M	637.10M
Transfusion Medicine Revenue Growth	-6.39%	-1.76%
Point of Care Revenue	601.60M	694.60M
Point of Care Revenue Growth	-13.39%	-22.15%
Molecular Diagnostics Revenue	26.50M	24.00M
Molecular Diagnostics Revenue Growth	10.42%	-24.29%
Revenue (Total)	2.73B	2.78B
Revenue (Total) Growth	-1.89%	-7.17%

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014
Period Ending	Dec '25 Dec 28, 2025	Dec '24 Dec 29, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 2, 2022	Jan '21 Jan 3, 2021	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014
North America Adjusted EBITDA	-	892.10M
North America Adjusted EBITDA Growth	-	-12.98%
EMEA Adjusted EBITDA	-	46.50M
EMEA Adjusted EBITDA Growth	-	13.41%
China Adjusted EBITDA	-	130.50M
China Adjusted EBITDA Growth	-	2.59%
Other Geographies Adjusted EBITDA	-	133.50M
Other Geographies Adjusted EBITDA Growth	-	15.78%
Corporate Adjusted EBITDA	-	-659.70M
Operating Income (Total)	-919.20M	-1.96B

Updated Dec 28, 2025. Data Source: Fiscal.ai.